Barclays keeps Buy on AbbVie despite 0.8% target gap
Alpha Vantage · The Globe and Mail · · AI-summarised by FinFlash
Barclays analyst Emily Field maintained a Buy rating on AbbVie with a $325.00 price target, following quarterly revenue of Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.Understand the context